Opens in a new tab
Free worldwide shipping
← All research
mTOR & Autophagy Unclassified

Therapeutic Drug Monitoring Of Sirolimus: Effect Of Concomitant Immunosuppressive Therapy And Optimization Of Drug Dosing

Source publication · 2004 · Cattaneo D, et al.

Research Summary

A retrospective laboratory study from an Italian central testing lab. It looked at how other transplant drugs given together with sirolimus (rapamycin) affect the sirolimus level measured in the blood, how much these levels vary, and whether a simple formula can predict the level after a dose change. Sirolimus shares a liver and gut breakdown pathway (the CYP3A4 enzyme) with several of these drugs.

Who Or What Was Studied?

Kidney transplant recipients from more than 40 Italian transplant centres. The lab analysed 2,658 sirolimus trough (lowest, pre-dose) blood samples from 495 patients, measured by HPLC between June 2001 and October 2003. Complete dose and treatment data were available for 689 samples from 189 patients. Patients took sirolimus with cyclosporine, tacrolimus, mycophenolate mofetil (MMF) and/or steroids.

What Did The Research Show?

  • For the same dose, sirolimus levels were higher with cyclosporine (4.15 ± 2.23 ng/mL per mg) than with MMF (3.26 ± 1.86 ng/mL per mg) or with MMF plus steroids (2.52 ± 1.73 ng/mL per mg).
  • Adding steroids to a cyclosporine-sirolimus regimen significantly lowered the dose-adjusted sirolimus level; a similar trend was seen with MMF.
  • Levels varied a lot: on average 19% within the same patient and 47% between patients, with the greatest variation in the first week after transplantation.
  • A simple formula (new level = old level × new dose ÷ old dose) predicted the level after a dose change within the accepted range in 73% of tested samples.

Limitations And Interpretation

  • A retrospective analysis of lab samples; doses and blood levels of the other drugs were not recorded.
  • Only trough levels were measured, not full drug exposure over the day, and blood levels may not reflect levels in the graft or immune tissues.
  • The patients were kidney transplant recipients on transplant doses, not healthy people or ageing-focused low-dose use.
  • The study did not test whether these level differences change rejection or graft outcomes; the authors call for prospective trials.

Summary prepared from the published paper (abstract and full text where accessible). This is not medical advice — always consult the original publication.

Source: publication record ↗